|
DUBLIN, Feb. 12, 2024 /PRNewswire/ -- The "Checkpoint Inhibitors Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.
The latest comprehensive research on the global checkpoint inhibitors market offers valuable insights into this burgeoning sector. The intensifying war against cancer has positioned checkpoint inhibitors as a critical combat instrument, which has significantly influenced the growth and trends in the industry.
The study examines the pivotal impetus driving this market scape and forecasts a striking expansion from $32.41 billion in 2023 to an estimated $37.88 billion in 2024, exhibiting a robust compound annual growth rate (CAGR) of 16.9%.
Key Drivers of Market Growth
Ingrained within the report is an analysis of the multifaceted drivers sustaining the upward trajectory of the checkpoint inhibitors landscape. The increasing prevalence of cancer cases globally serves as a primary catalyst fueling the demand for more effective treatment modalities. This is complemented by the momentum gained through breakthrough FDA approvals, strategic industrial partnerships, and the surge in healthcare spending dedicated to innovative pharmaceuticals and preventive care measures.
The report foresees further expansion of the checkpoint inhibitors market, projecting a valuation of $55.64 billion by 2028, with a steady CAGR of 10.1%. Such growth is anticipated to stem from the extension of indications for existing checkpoint inhibitors, advancements in biomarker discoveries, and the burgeoning significance of combination therapies that tailor to personalized medicine approaches.
Regional Dynamics and Leading Segments
The report not only provides a global outlook but also zooms in on specific regional hotspots. North America is pinpointed as the dominant force within the market in 2023. Meanwhile, the Middle East is earmarked as the fastest-growing region during the forecast period, underscoring the potential for investment and development in emerging markets.
On the forefront of innovation, major players have made significant strides in the market segment pertaining to PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, and groundbreaking CAR-T cell therapies. This diversification in drug categories leads to novel therapeutics that cater to a variety of malignancies, including lung, renal, blood, bladder cancers, and melanoma.
- The report analyzes the sector's application in varying distribution channels such as hospital pharmacies, retail pharmacies, and online services, reflecting the extensive reach of checkpoint inhibitors across healthcare settings.
- Also highlighted within the industry analysis are the evolving competitive strategies, with leading enterprises delving into acquisitions and collaborations to fortify their market holdings and pipeline portfolios.
- Essential to the comprehensive nature of the research, the market valuation encompasses factory gate values indicating the direct economic contribution of the manufacturers.
The checkpoint inhibitors market research consolidates an array of data, presenting an all-encompassing view for stakeholders. The publication provides an in-depth, current, and future market scenario, crafted to meet the demands for knowledgeable decision-making in the rapidly evolving checkpoint inhibitors landscape.
This comprehensive report on the global checkpoint inhibitors market stands as an invaluable asset for investors, healthcare professionals, policymakers, and all entities engaged in the healthcare sector, to navigate through the complexities and leverage the opportunities within the thriving checkpoint inhibitors market.
Companies Profiled
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Merck & Co. Inc.
- Roche Holding AG
- Pfizer Inc.
- Incyte Corporation
- Novartis AG
- NewLink Genetics Corporation
- Seattle Genetics Inc.
- Celldex Therapeutics
- GlaxoSmithKline plc
- Innate Pharma S.A.
- Ono Pharmaceutical Co. Ltd.
- Juno Therapeutics
- Kite Pharma
- Eli Lilly and Company (ARMO Biosciences.)
- Fortress Biotech
- Argenx SE
- MacroGenics
- CureTech
- Sorrento Therapeutics
- Sanofi S.A
- F. Hoffmann-La Roche Ltd
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Bayer AG
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Gilead Sciences Inc.
- Kyowa Kirin Co. Ltd.
- Johnson & Johnson
- Regeneron Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Incorporated
- Y-mAbs Therapeutics Inc.
- Zai Lab Limited
For more information about this report visit https://www.researchandmarkets.com/r/oajoiq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
 View original content:https://www.prnewswire.com/news-releases/checkpoint-inhibitors-market-forecast-reveals-impressive-growth-with-focus-on-novel-therapies-and-regional-expansion-302059742.html
SOURCE Research and Markets
|
